Crispr Therapeutics, a gene editing drug developer backed by Bayer, Vertex, Celgene and GlaxoSmithKline, has set the terms for an offering on Nasdaq.
Switzerland-based gene editing technology developer Crispr Therapeutics has set the range for its initial public offering between $15 and $17 a share and could raise up to $79.9m when it floats.
Crispr, which is backed by investors including pharmaceutical group Bayer, intends to issue 4.7 million shares on Nasdaq and, should it float at the top of its range, will do so at a fully diluted market cap of approximately $710m.
Crispr is developing treatments for a range of…
